Canada markets close in 1 hour 13 minutes

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.0000+0.0100 (+0.50%)
As of 01:48PM EDT. Market open.
Full screen
Previous Close1.9900
Open2.0100
Bid2.0000 x 0
Ask2.0300 x 0
Day's Range1.9800 - 2.0300
52 Week Range1.5200 - 3.3300
Volume13,816
Avg. Volume45,715
Market Cap92.539M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-0.3680
Earnings DateAug 17, 2022 - Aug 22, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
  • Newsfile

    NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - May 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock options to a director exercisable at a price of $2.08 per share for a period of five years with vesting that is either time or performance based. All ...

  • Newsfile

    NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)

    Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James GuestNervGen will also present at the International Investment Forum Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class

  • Newsfile

    NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results

    Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical ...